ALT

Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver disease. Headquartered in Gaithersburg, Maryland, the company advances a pipeline of innovative therapeutics targeting metabolic dysfunction and related conditions. Altimmune's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist in Phase 2 clinical trials for obesity and metabolic dysfunction-associated steatohepatitis (MASH). The company also develops HepTcell, an immunotherapy for chronic hepatitis B, currently in Phase 2 studies. Altimmune operates with a streamlined business model, focusing resources on clinical development while utilizing contract research organizations and manufacturing partners to manage costs. The company employs approximately 50 people and maintains research operations in its Maryland facility. In recent developments, Altimmune has reported positive clinical data for pemvidutide, demonstrating significant weight loss and metabolic improvements in trial participants, positioning the compound as a potential competitor in the rapidly expanding obesity therapeutic market. The company finances operations primarily through equity offerings and strategic partnerships. Altimmune trades on the Nasdaq stock exchange under the ticker symbol ALT and maintains an active clinical development strategy aimed at advancing its pipeline toward potential commercialization in high-value therapeutic areas with substantial unmet medical needs.